Pharmacogenomics of cisplatin-based chemotherapy in ovarian-cancer patients from Yakutia

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Molecular Genetics Microbiology and Virology

• Publication date

  2013-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3103/S0891416813040034
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Attenuation of Cisplatin-Induced Renal Injury by Inhibition of Soluble Epoxide Hydrolase Involves Nuclear Factor κB Signaling

  2012cited by this paper
• Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins.

  2012cited by this paper
• Drug-Induced Oxidative Stress and Toxicity

  2012cited by this paper
• Germline pharmacogenomics in oncology: Decoding the patient for targeting therapy

  2012cited by this paper
• Genetic variants of NBS1 predict clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer in Chinese.

  2012cited by this paper
• High p27 expression is associated with a better prognosis in East Asian non-small cell lung cancer patients.

  2011cited by this paper
• Allelic variant at -79 (C>T) in CDKN1B (p27Kip1) confers an increased risk of thyroid cancer and alters mRNA levels.

  2010cited by this paper
• Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer.

  2009cited by this paper
• Pharmacogenomics: a tool for improving cancer chemotherapy

  2008cited by this paper
• The resurgence of platinum-based cancer chemotherapy

  2007cited by this paper
• Direct cellular responses to platinum-induced DNA damage.

  2007cited by this paper
• Molecular mechanisms of resistance and toxicity associated with platinating agents.

  2007cited by this paper
• PowerMarker: an integrated analysis environment for genetic marker analysis

  2005cited by this paper

• Navigating the Genetic Risk of Chemotherapy-Induced Hearing Loss in the Stria Vascularis.

  2025cites this paper
• The Role of Genetic and Non-Genetic Factors in the Occurrence of Cisplatin-Associated Ototoxicity

  2025cites this paper
• Genomic instability in ovarian cancer: Through the lens of single nucleotide polymorphisms.

  2024cites this paper
• Cisplatin-Induced Hearing Loss, Oxidative Stress, and Antioxidants as a Therapeutic Strategy—A State-of-the-Art Review

  2024cites this paper
• Pharmacogenetics of chemotherapy treatment response and -toxicities in patients with osteosarcoma: a systematic review

  2022cites this paper
• The genetic vulnerability to cisplatin ototoxicity: a systematic review

  2019cites this paper
• Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review

  2018cites this paper
• Ethnic Differences in Susceptibility to the Effects of Platinum- Based Chemotherapy

  2018cites this paper
• An investigation of the pharmacogenetic basis of toxicity to platinum chemotherapy agents

  2016cites this paper